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ABSTRACT
Objectives Identification of patients at increased mortality 
risk is important in the context of increasing multimorbidity 
and an ageing population, to help facilitate the planning 
and delivery of services. The aim of this study was to 
examine 1- year all- cause mortality in a cohort of primary 
care patients in whom inflammatory markers including 
C reactive protein (CRP), erythrocyte sedimentation rate 
(ESR) and plasma viscosity (PV), had been tested.
Design Observational cohort study using general 
practitioner Electronic Health Records from the Clinical 
Practice Research Datalink, with linkage to Office for National 
Statistics (ONS) Death Registry.
Setting UK Primary Care.
Participants 159 325 patients with inflammatory marker 
tests done in 2014 and 39 928 age, sex and practice- 
matched controls without inflammatory marker testing. 
ONS Death registry data were available for 109 966 
participants.
Primary and secondary outcome measures One- year 
mortality in those with raised inflammatory markers 
compared with normal inflammatory markers and untested 
controls. Subanalyses stratified 1- year mortality by age 
group, gender and cause of death.
Results Patients with a raised inflammatory marker 
(n=47 797) had an overall 1- year all- cause mortality 
of 6.89%, compared with 1.41% in those with normal 
inflammatory markers (p<0.001) and 1.62% in untested 
controls. A raised CRP is associated with the highest 
mortality rate at 8.76% compared with 4.99% for ESR and 
4.66% for PV. One- year mortality is higher in men with a 
raised inflammatory marker compared with women (9.78% 
vs 5.29%). The C- statistic of a simple mortality prediction 
model containing age, sex and CRP test result is 0.89.
Conclusions Inflammatory markers are a strong predictor 
of all- cause mortality in primary care, with a C- statistic 
comparable to several previously developed frailty indices. 
Future research should consider the added value of CRP 
testing, in combination with other risk factors, to improve 
prediction of mortality in primary care. Evidence- based 
interventions for frailty are needed alongside predictive tools.
BACKGROUND
Identification of patients at increased risk 
of mortality is important in the context of 
increasing multimorbidity and an ageing 
population, with the aim of helping facilitate 
the planning and delivery of services. Multiple 
risk tools have therefore been developed to 
predict mortality; these can be used to help 
predict frailty, unplanned hospital admis-
sions and to allow targeted interventions to 
people at an increased mortality risk. The 
National Institute for Health and Care Excel-
lence multimorbidity guidelines systemati-
cally reviewed 41 of these mortality risk tools; 
the majority were of low or very low quality 
and a need for further research in this area 
was identified.1 Current risk tools include 
variables such as disease status, sociodemo-
graphic factors and laboratory test results (eg, 
anaemia, raised platelets), however, none in 
current use include an inflammatory marker 
test.
Inflammatory markers such as C reac-
tive protein (CRP), erythrocyte sedimenta-
tion rate (ESR) and plasma viscosity (PV) 
are commonly used in primary care to aid 
diagnosis and monitoring of infections and 
inflammatory conditions. Cohort studies 
in the general population have reported 
inflammatory markers as predicting future 
Strengths and limitations of this study
 ► The main strength of this study is its size and setting 
in primary care, making results relevant to clinical 
practice.
 ► As test results were transferred electronically to the 
general practitioners record, there is a very low risk 
of transcription error or bias.
 ► Use of ONS death registry data increased the accu-
racy of recording of mortality, the primary outcome.
 ► Main limitation is the lack of information on the rea-
sons for testing.
 ► Previous studies have focused on predictors of mor-
tality in the elderly, yet we were able to study mor-
tality across all age groups.
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mortality,2–4 particularly from cardiovascular disease.5 
CRP has also been shown to have predictive value for 
mortality in hospital settings.6–8 The clinical relevance 
of these findings in primary care settings, and over the 
shorter term, has not previously been described.
The aim of this study was to examine 1- year all- cause 
mortality in a cohort of primary care patients in whom 
inflammatory marker bloods had been tested.
METHODS
This was a secondary analysis of an observational cohort 
study of 160 000 patients aged >18 from the Clinical 
Practice Research Datalink (CPRD) with inflamma-
tory marker blood testing in 2014, and 40 000 age, sex 
and practice- matched controls without inflammatory 
marker testing also in 2014. The methods have been 
described fully in previous paired papers describing 
the disease outcomes following inflammatory marker 
testing.9 10 Patients were excluded from the analysis 
if the inflammatory marker test result was missing 
(n=673) or if results were so abnormal as to be consid-
ered spurious (n=2). Linkage to ONS death registry 
data was available for 109 966. The three inflamma-
tory marker tests studied were CRP, ESR and PV. We 
defined a raised inflammatory marker using the mean 
upper limit of normal for laboratories within our study. 
For CRP this was 6.8 mg/L, for simplicity rounded to 
7 mg/L; for PV 1.72 mPa.s. For ESR this mean upper 
limit of normal was rounded and stratified by gender 
and age.9 When the same inflammatory marker was 
repeated on the same day (n=231), we retained the 
highest value. The index date was defined as the first 
date of inflammatory marker testing in 2014, with 
1- year mortality defined as death within 1 year of this 
index date. Date of death was defined as the earlier 
date of recorded death in either CPRD or ONS death 
registry. Cause of death was available from death certi-
fication data in 3141 out of 5512 deaths where ONS 
linkage was available.
Analysis
The primary analysis compared 1- year mortality in those 
with raised versus normal inflammatory markers and 
compared with untested controls. Subanalyses stratified 
1- year mortality by age group and gender and cause of 
death. For each of the three tests (CRP, ESR and PV), 
dichotomised test results were cross- classified with the 
reference standard 1- year mortality, allowing sensitivity 
and specificity to be calculated. Logistic regression was 
used to calculate diagnostic ORs, with and without adjust-
ment for age and gender.
Test results were also analysed on a continuous 
scale, using logistic regression to determine the dose 
response relationship between inflammatory marker 
test result and mortality. The area under receiver 
operator curve, otherwise known as the C- statistic, was 
calculated using a logistic regression model using test 
result on a continuous scale, with log transformation 
due to the skewed nature of the data, with and without 
age and gender as covariates. Comparisons of the C- sta-
tistic were made using DeLong method.11 All analyses 
were done using Stata V.15.12
Patient and public involvement
Patients were not involved in the design, conduct, 
reporting or dissemination of this research.
RESULTS
Demographics of the tested cohort and untested controls, 
compared with the UK population are shown in online 
supplemental table 1. After exclusions there were 159 325 
tested patients of whom 114 198 (71.7%) had a CRP test, 
92 325 (58.0%) an ESR test and 15 994 (10%) a PV test; 
62 789 (39.4%) had more than one inflammatory marker 
performed simultaneously, mostly CRP and ESR together 
(51 546). Overall 47 797 (30%) had one or more raised 
inflammatory marker on the index date. In total 5512 
patients died within 1 year of the index date; 648 deaths 
in the untested group, 1572 deaths in the normal inflam-
matory marker group and 3292 deaths in the group with 
one or more raised inflammatory marker.
Overall mortality rates
Table 1 shows overall mortality rates subdivided by age, 
gender and test results. Patients with a raised inflamma-
tory marker (n=47 797) had an overall 1- year mortality 
of 6.89%, compared with 1.41% in those with normal 
inflammatory markers (p<0.001). In the untested 
comparison cohort, 1- year mortality was 1.62%. The asso-
ciation between raised inflammatory markers and 1- year 
mortality was seen in all age groups apart from the under 
30 years old. In older age groups the absolute increase 
in risk was considerable; a raised inflammatory marker 
in the over 80s was associated with a 1- year mortality of 
21.8%, compared with 8.6% in the over 80s with normal 
inflammatory markers.
Men with a raised inflammatory marker had a signifi-
cantly higher 1- year mortality rate than women with a 
raised inflammatory marker (9.78% vs 5.29%). Patients 
with a raised CRP had a 1- year mortality of 8.76% 
compared with 4.99% for those with raised ESR and 
4.66% for raised PV.
In the 62 789 patients with more than one inflamma-
tory marker performed simultaneously on the index 
date, 1- year mortality was higher in the 9029 patients with 
concordant raised values at 6.9%, compared with the 
13 783 with discordant results (one raised, one normal) 
who had a 1- year mortality of 2.8%. In the 39 977 patients 
with two simultaneous negative inflammatory markers 
1- year mortality was 0.85%.
Table 2 shows the performance characteristics of 
inflammatory markers, including sensitivity, specificity 
and C- statistic. CRP had the highest sensitivity of the 
three tests at 67.8% and the greatest C- statistic at 0.78. OR 
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reduced after adjustment for age and gender but were 
still significant with an adjusted OR for a raised CRP of 
4.5 (p<0.001), 2.9 for raised ESR and 2.1 for raised PV.
A logistic regression model containing age (as a 
continuous variable) and gender had a C- statistic of 
0.85, compared with 0.89 for a full model containing 
age, gender and CRP test result as a continuous variable 
(p<0.001); 0.88 with age, gender and ESR (p<0.001); and 
0.87 with age gender and PV (p<0.001).
Repeat testing
Figure 1 shows the 1- year mortality in patients according 
to the subsequent repeat inflammatory marker results, 
using the most common test performed; CRP. The fact 
that a CRP test was requested by a general practitioner 
(GP) was in itself, predictive of increased mortality, with 
1- year mortality of 3.3% in the tested vs 1.6% in the 
untested cohort. This increased to 8.76% 1- year mortality 
if a single CRP test was raised, 9.13% if a second test was 
persistently raised and 14.5% if the second test was raised 
further still. Those with a raised inflammatory marker 
which was not subsequently rechecked had a 1- year 
mortality rate of 10.2%, compared with 3.25% if a subse-
quent CRP normalised.
Dose–response relationship
A dose–response relationship was found between result 
of the index CRP test as a continuous variable and 1- year 
mortality (figure 2). In 2184 people with a CRP ≥100 mg/L 
overall 1- year mortality was 20.2%. Similar associations, 
with wider CIs, were found for ESR and PV (not shown).
Cause of death
Cause of death from ONS death certification was available 
for 3141 out of 5512 total deaths in the cohort. Table 3 
summarises the cause of death among patients with raised 
inflammatory markers, compared with those with normal 
inflammatory markers and untested controls. The most 
common cause of death in the 26 507 patients with raised 
inflammatory markers was cancer (696 deaths), followed 
by cardiovascular disease (449 deaths). Odds of mortality 
in the raised versus normal inflammatory marker groups 
was highest for cancer (adjusted OR 6.34), followed by 
infections (adjusted OR 4.11). However, significant 
increased odds of mortality were seen for all disease cate-
gories with the exception of deaths due to falls, musculo-
skeletal causes and senility. Online supplemental table 2 
shows cause of death by age group for patients with raised 
inflammatory markers; cancer was the most common 
cause of death in 40–79 years old, cardiovascular disease 
increased with age and was the most common cause of 
death in the over 80 age group.
DISCUSSION
Inflammatory markers are a strong predictor of all- cause 
mortality in primary care. The association between raised 
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all age groups except patients aged less than thirty years. 
Men with raised inflammatory markers have a higher 
1- year mortality than women (9.78% vs 5.29%). Of the 
three tests examined, CRP has the highest predictive 
accuracy for mortality. The overall C- statistic of a model 
containing age, sex and CRP test result of 0.89 is compa-
rable to several previously developed frailty indices. 
Inflammatory markers could potentially be a simple indi-
cator to improve prediction of life expectancy in primary 
care.
Strengths and limitations
The major strength of this study is its size and its setting 
in primary care, making results relevant to clinical prac-
tice. As test results were transferred electronically to the 
GP record, there is a very low risk of transcription error 
or bias. Use of ONS death registry data increased the 
accuracy of recording of mortality, the primary outcome. 
Previous studies have focused on predictors of mortality 
in the elderly, yet we were able to study mortality across 
all age groups. The fact that mortality is not raised in 
patients with a normal inflammatory marker suggests that 
the test result, rather than the clinician’s decision to test, 
is significant.13
The main weakness is the lack of information about 
the reasons for testing; we cannot determine which tests 
were done for diagnosis, monitoring or non- specific 
purposes. However, this is also a strength, as it increases 
the generalisability of the results, which are not limited to 
specific subgroups of tested patients.
Comparison to previous literature
Several previous frailty indices have previously been 
developed, the most commonly used being the electronic 
Frailty Index)14 and Qmortality.15 The former has a C- sta-
tistic of 0.76; the latter a C- statistic of 0.85 for women and 
0.84 for men. More recent research by Deelen et al has 
used combinations of biomarkers to predict mortality 
across all age groups; 226 potential biomarkers were 
selected, but CRP, ESR and PV were not considered.16 
They generated a model using 14 biomarkers with a C- sta-
tistic of 0.837: however, of the biomarkers considered, 
only albumin is available in primary care, limiting the 
clinical usefulness of their findings. CRP by comparison 
is a low cost and widely available test. With a C- statistic of 
0.78 for CRP alone, and 0.89 for a model including CRP, 
age and gender, inflammatory markers could be a simple 
indicator with a comparable accuracy to currently used 
mortality prediction tools.
The association between CRP and mortality is in 
keeping with population- based studies examining all- 
cause mortality2 17 and cardiovascular mortality,5 as well 
as hospital- based studies of patients with specific diseases 
including COPD,18 diabetes,19 chronic kidney disease,8 20 
Table 2 Performance characteristics of CRP, ESR and PV for predicting 1- year mortality
Sensitivity Specificity C- statistic*
Univariable logistic 
regression
Adjusted for age and 
gender
OR P value OR P value
CRP 67.8% (66.3–69.3) 75.9% (75.6–76.2) 0.78 (0.77–0.78) 6.6 (6.2 to 7.1) <0.001 4.5 (4.2 to 4.8) <0.001
ESR 56.6% (54.4–58.7) 75.7% (75.4–75.9) 0.66 (0.65–0.67 4.1 (3.7 to 4.4) <0.001 2.9 (2.7 to 3.2) <0.001
PV 52.0% (47.0–56.9) 72.1% (71.3–72.8) 0.62 (0.60–0.64) 2.8 (2.3 to 3.4) <0.001 2.1 (1.7 to 2.6) <0.001
*C- statistic calculated using log transformed test results as a continuous variable.
CRP, C reactive protein; ESR, erythrocyte sedimentation rate; PV, plasma viscosity.
Figure 1 Flow chart of 1- year mortality (95% CIs) according 
to CRP test results. The right- hand column shows 1- year 
mortality according to repeat test result; defined as the first 
CRP test performed in the 3 months following the index date. 
CRP, C reactive protein.
Figure 2 Polynomial logistic regression of mortality against 
CRP test result as a continuous variable. CRP, C reactive 
protein.
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pneumonia6 and cancer.21 22 The research reported here 
demonstrates that this association is also seen in a primary 
care setting and over the shorter term. The finding that 
men with raised inflammatory markers are at higher 
mortality risk than women may reflect gender differences 
in healthcare- seeking behaviour in primary care; men 
have lower rates of consultation, so might be ‘sicker’ on 
average when presenting for blood tests.
Previous research has shown limited diagnostic utility 
of inflammatory markers in a primary care setting, 
where sensitivity is low, false positives are common, and 
abnormal tests can lead to increased rates of GP consul-
tations, tests and referrals.9 The fact that inflammatory 
markers have a higher C- statistic for mortality than for 
cancer, infections or autoimmune diseases,10 may reflect 
the fact that inflammatory markers have both diagnostic 
and prognostic utility for a broad range of pathologies.
Clinical implications
GPs should interpret raised inflammatory markers within 
the wider clinical context; where the cause of inflamma-
tion is identifiable and treatable, mortality risks should 
not cause undue alarm. The findings back up the current 
clinical practice of repeating an abnormal test; a subse-
quent normal result is reassuring with mortality risk 
reducing to near normal. However, clinicians should 
consider whether older patients with a persistently raised 
inflammatory markers are reaching the end of life.
There is debate over the utility of predicting mortality,23 
given the lack of evidence- based interventions. We would 
not recommend that clinicians test inflammatory markers 
purely for the purpose of mortality prediction, particu-
larly given that false positives have been shown to lead to 
cascades of follow on tests, appointments and referrals.9 
However, GPs are already required to identify patients 
who are frail,24 and inflammatory marker tests are 
commonly performed for many other reasons. Inflam-
matory marker test results, when available, may therefore 
add useful information to improve prediction of mortality 
and assessment of frailty in primary care.
Unanswered questions and future research
Future research should consider the added value of CRP 
testing in combination with other risk factors, to improve 
prediction of mortality in primary care. Predicting 
mortality in itself, however, is not enough, as tests will only 
benefit patients if they influence management. Evidence- 
based interventions for frailty must therefore be devel-
oped alongside predictive tools.
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